Summary
Background
The introduction of more sensitive techniques, such as Luminex® for HLA antibody screening of patients awaiting organ transplantation has resulted in a better understanding of transplantation immunology and improvements in clinical practice.
Objective
The interpretation of the results obtained only by Luminex® can lead to inaccurate evaluation of a patient’s antibody status and unjustified rejection of a potential organ donor. The aim of this study was to demonstrate the benefits of performing HLA antibody screening in the sera of patients on the waiting list for organ transplantation by two different assays, complement dependent cytotoxicity (CDC) and Luminex®.
Methods
A retrospective analysis was performed on 563 pretransplant serum samples from 141 patients on the kidney transplantation waiting list in Rijeka, tested from March 2012 until March 2015. All samples were tested in parallel by the CDC assay and the Luminex®-based assay.
Results
Out of the 563 samples tested 302 (53.7%) tested negative for HLA antibodies and 88 (15.6%) positive by both assays. From 173 (30.7%) samples with discordant results 149 (26.5%) were CDC negative and Luminex® positive, while 24 (4.3%) were CDC positive and Luminex® negative. Among the Luminex positive patients seven did not experience any immunizing events.
Conclusion
Evaluation of the HLA antibody status in patients on a waiting list for organ transplantation should be based on the results of the both CDC and Luminex® (or other sensitive) assays in accordance to information about patient’s clinical status and exposure to immunizing events.
Similar content being viewed by others
References
Lobashevsky AL. Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation. World J Transplant. 2014;4(3):153–67.
Terasaki PI, Kreisler M, Mickey RM. Presensitization and kidney transplant failures. Postgrad Med J. 1971;47:89–100.
Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol. 2005;17:541–5.
Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol. 2009;70(8):589–94.
Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002;74(10):1377–81.
Süsal C, Opelz G. Impact of HLA matching and HLA antibodies in organ transplantation. A collaborative transplant study view. Methods Mol Biol. 2012;88:267–77.
Jawdeh ABG, Cuffy MC, Alloway RR, Shields AR, Woodle ES. Desensitization in kidney transplantation: review and future perspectives. Clin Transplant. 2014;28(4):494–507.
Paramesh AS, Zhang R, Baber J, et al. The effect of HLA mismatch on highly sensitized renal allograft recepients. Clin Transplant. 2010;24(6):E247–E252.
Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature. 1964;204:998–1000.
Gebel HM, Bray RA, Nicherson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant. 2003;3:1488–500.
Patel R, Terasaki PI. Significance of the positive cross-match test in kidney transplantation. N Engl J Med. 1969;280:735–9.
Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, et al. “Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation. 2008;86(8):1111–5.
Süsal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leucocyte antigen antibodies detected exclusively by sensitive luminex-single antigen testing: a collaborative transplant study report. Transplantation. 2011;91(8):883–7.
Grubić Z, Žunec R, Čečuk-Jelić E, Kerhin-Brkljačić V, et al. Polymorphism of HLA-A,-B,-DRB1,-DQA1 and -DQB1 haplotypes in Croatian population. Eur J Immunogenet. 2000;27(1):47–51.
Mehra KN. The role of HLA matching and recipient sensitization in organ allograft outcom. In: Tait BD, editor. The HLA complex in biology and medicine: A resource book, 1st edn. Chapter 29. New Delhi: Jaypee Brothers Medical Publisher; 2010. pp. 491–509.
Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, Süsal C. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant. 2013;13(8):2075–82.
Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant. 2001;16:897–904.
Süsal C, Dohler B, Sadeghi M, Ovens J, Opelz G. HLA antibodies and occurrence of early adverse events inthe modern era of transplantation: a collaborative transplant study report. Transplantation. 2009;87:1367–71.
Everly MJ. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients. Clin Transpl. 2011;(2011):333–6.
Tait BD, Süsal C, Gebel HM, Nickerson PW, et al. Consesus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95:19–47.
Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leucocyte antigen flow cytometry beads for accurate identification of human leucocyte antigen antibody specificities. Transplantation. 2003;75:43–9.
Colombo MB, Haworth SE, Poli F, et al. Luminex technology for anti-HLA antibody screening: evaluation on performance and of impact on laboratory routine. Cytometry B Clin Cytom. 2007;72((6):465–71.
Tait BD, Hudson F, Cantwell L, Brewin G, et al. Review article: luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton). 2009;14:247–54.
Pereira S, Perkins S, Lee JH, et al. Donor-specific antibody against denatured HLA-A1: non clinically significant? Human Immunol. 2011;72:492–8.
Tait BD, Hudson F, Brewin G, Cantwell L, et al. Solid phase HLA antibody detection technology – Challenges in interpretation. Tissue Antigens. 2010;76:87–95.
Acknowledgements
The authors thank all staff members of our HLA laboratory for great technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
N. Katalinić, M. Fućak, T. Crnić, M. Ćurković, A. Starčević and S. Balen declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Katalinić, N., Fućak, M., Crnić, T. et al. Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays. Wien Klin Wochenschr 129, 33–37 (2017). https://doi.org/10.1007/s00508-016-1094-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-016-1094-6